TransThera Sciences (Nanjing), Inc. (the “Company”) has announced its intention to repurchase H shares on the open market for an aggregate amount not exceeding RMB100.00 million, or the equivalent in Hong Kong dollars. The initiative will be executed under the general repurchase mandate approved by shareholders at the Company’s annual general meeting (AGM) on 18 June 2026.

The repurchase window opens immediately following the AGM approval and will remain in effect until the earliest of: 1) the conclusion of the next AGM; 2) the statutory deadline for holding the next AGM; or 3) any revocation or amendment of the mandate by shareholders via special resolution.

Management stated that the programme will be funded with resources permissible under applicable laws, and the repurchased shares may be cancelled, held in treasury, sold, or transferred as determined by the Board. All transactions will adhere to the Listing Rules of The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, the Company’s articles of association, and relevant PRC regulations.

The Board believes the buyback will signal confidence in the Company’s business outlook while maintaining a solid financial position. As of the announcement date, no H shares have been repurchased. Execution of the programme remains subject to market conditions and the Board’s discretion, and there is no assurance on the timing, quantity, or pricing of any purchases.

Investors are advised to exercise caution when dealing in the Company’s securities.